<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256100</url>
  </required_header>
  <id_info>
    <org_study_id>2004.066</org_study_id>
    <nct_id>NCT00256100</nct_id>
  </id_info>
  <brief_title>Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.</brief_title>
  <official_title>Assessment of the Safety and Efficacy of Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Renal Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melbourne Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new
      drug to prevent blood clotting in the continuous dialysis machine used in intensive care
      patients who have kidney failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study hypothesis is that when used as an anticoagulant in haemofiltration, fondaparinux
      prolongs the filter life when compared to enoxaparin.

      Fondaparinux is the first compound of a new class of synthetic oligosaccharides with
      antithrombotic effects. It represents the active portion of the natural heparin molecule.

      The null hypothesis is that there is no difference in filter life when using fondaparinux or
      enoxaparin as anticoagulation for haemofiltration.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Teh Priincipal investigator responsible for the trial no longer employed at the study site.
  </why_stopped>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The study will evaluate the duration of filter patency using fondaparinux as an anticoagulant in haemofiltration and compare this to the current standard haemofilter anticoagulant, enoxaparin.</measure>
    <time_frame>Duration of the haemofilter life</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence of complications, primary bleeding with fondaparinux compared to enoxaparin in this setting.</measure>
    <time_frame>Until hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>One</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fondaparinux will be used as the anticoagulant in the sencond arm of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux Sodium</intervention_name>
    <description>The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation</description>
    <arm_group_label>One</arm_group_label>
    <arm_group_label>Two</arm_group_label>
    <other_name>Arixtra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (18 years or over) admitted to the ICU and expected to stay for more
             than 48 hours.

          2. Patients who require continuous renal replacement therapy.

          3. Patients who consent or if the patient is not competent, the next of kin who consent
             to inclusion in the study. .

        Exclusion Criteria:

          1. Patients aged less than 18 years of age.

          2. Patients who are pregnant

          3. Patients with a contraindication to anticoagulation for pre existing bleeding
             diathesis

          4. Patients or next of kin who do not consent to study inclusion. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F Cade</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital Intensive Care Unit Grattan Street</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2005</study_first_submitted>
  <study_first_submitted_qc>November 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

